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A B S T R A C T
Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common comorbid disorder in patients suf-
fering from substance use disorder (SUD). Individuals with co-occurring SUD and ADHD are more likely than
SUD patients without ADHD to have developed SUD at a younger age, be polysubstance users, and need inpatient
treatment more often. The present study investigates whether individuals with polysubstance use disorder who
remain abstinent for a year after entering treatment have a more substantial reduction in ADHD symptoms than
those who relapsed and controls.
Material and methods: Subjects were SUD patients (N = 115) and healthy controls (N = 34). ADHD symptoms
were assessed using the adult ADHD Self-Report Scale (ASRS). Substance use was assessed by self-reports on the
Alcohol Use Disorders Identification Test (AUDIT) and the Drug Use Disorders Identification Test (DUDIT).
Participants were defined as having relapsed if they had an AUDIT score ≥ 8 or a DUDIT score ≥ 2 for women
and ≥ 6 for men.
Results: Patients who remained abstinent for one year reported a substantial reduction of ADHD symptoms
compared to patients who relapsed and controls.
Conclusions: Abstinence alleviates ADHD symptoms among patients with polysubstance use disorder. We suggest
that confirmation of an ADHD diagnosis should follow a period of abstinence to avoid identification of false-
positive cases.
1. Introduction
One of the most common disorders associated with substance use
disorder (SUD) is attention-deficit/hyperactivity disorder (ADHD)
(Brook, Whiteman, Cohen, Shapiro, & Balka, 1995; Kessler et al., 2006;
Wilens & Spencer, 2010). Nearly 25% of the adults between 18 and
44 years old who have been diagnosed with SUD in the United States
have also been diagnosed with ADHD (Kessler et al., 2006). Other
studies show that 40% of clinical SUD samples in different countries
screened positive for ADHD (Glind et al., 2013; van Emmerik-van
Oortmerssen et al., 2012).
ADHD has an adverse effect on the course of SUD (McAweeney,
Rogers, Huddleston, Moore, & Gentile, 2009; Wilens et al., 2011). Re-
lative to SUD patients without ADHD, SUD patients with ADHD are
more likely to have developed SUD at a younger age, become poly-
substance users, and need inpatient treatment more often (Arias et al.,
2008; Tamm et al., 2013). Also, SUD patients who screen for a con-
current adult ADHD diagnosis have been shown to have more severe
and chronic SUD (Young et al., 2015), and a childhood ADHD diagnosis
in SUD patients is associated with higher relapse rates after treatment
termination (Carroll & Rounsaville, 1993).
ADHD is manifested in childhood, and it persists into adolescence in
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T
almost 75% of the cases, and into adulthood in close to 50%
(Wilens & Spencer, 2010). Most studies have focused on how the onset
of ADHD, often in combination with conduct or bipolar disorders, in-
creases the risk of later SUD (Wilens et al., 2011).
Comorbid ADHD place patients with SUD at risk of impaired re-
covery, with longer duration of substance use and slower remission rate
(Wilens, Biederman, &Mick, 1998).
SUD complicates the diagnostic process, particularly for clients
identified with ADHD in adulthood and for those with symptoms below
the diagnostic threshold (Levin, Evans, & Kleber, 1998). Diagnosing
ADHD in adult patients with SUD requires accurate retrospective in-
formation, and this is often difficult to obtain because of inadequate
anamnestic data (Faraone et al., 2007; Levin et al., 1998). Conse-
quently, there is a group of adults who meet all the criteria for an ADHD
diagnosis except age at onset (Faraone et al., 2007). However, studies
have found that this group has similar forms of psychiatric comorbidity,
neurocognitive impairment, and familial transmission as the group with
a confirmed diagnosis, only differing on the childhood onset require-
ment of the Diagnostic and Statistical Manual of Mental Disorders-
Fourth Edition (DSM-IV) (Faraone et al., 2006; Faraone et al., 2006).
Furthermore, because SUD often emerges in adolescence, the apparent
late onset of ADHD may reflect the onset of SUD rather than ADHD, and
although subthreshold ADHD may be a milder form of the disorder
(Norén Selinus et al., 2016), it could also reflect nonspecific risk
characteristics for SUD rather than symptoms of ADHD (Faraone et al.,
2006). Taken together, this means that improvement of SUD symptoms
may also lead to an improvement of problems associated with ADHD
symptoms.
The present study investigates how 12 months of sobriety following
the onset of treatment affects the presence of self-reported ADHD
symptoms in a clinical sample of polysubstance users. Polysubstance
use disorder is frequent in clinical SUD samples (Andrade,
Carroll, & Petry, 2013). Comorbid ADHD place patients with SUD at risk
of impaired recovery, with longer duration of substance use and slower
remission rate (Wilens et al., 1998).
To our knowledge, this is the first study to report changes in self-
reported ADHD symptoms in people with polysubstance use disorder
during the 12-month period after initiation of treatment. Using a pro-
spective design and a control group, we addressed the following ques-
tion: Will individuals with polysubstance use disorder who remain ab-
stinent for one-year show a greater improvement in ADHD symptoms
compared with those who relapsed and controls?
2. Material and methods
2.1. Participants
One hundred and fifty SUD patients were recruited from 10 out-
patient and residential treatment facilities within the Stavanger
University Hospital catchment area (Norway) between March 2012 and
May 2013. We employed broad inclusion criteria focusing on poly-
substance use disorder because it is common in clinical settings
(Badiani, Belin, Epstein, Calu, & Shaham, 2011; Stavro,
Pelletier, & Potvin, 2013). The main inclusion criteria at baseline were:
(a) evidence of SUD with polysubstance use, operationalized as the use
of more than one drug on a single occasion, or a history of abusing
multiple drugs; (b) enrolled in a new treatment sequence by the sub-
stance use treatment service; and (c) at least 16 years of age. At base-
line, 22 patients were excluded because they did not meet the inclusion
criteria (four had no substance use addiction and 18 did not report
polysubstance use), leaving 128 patients in the study.
The control group (N = 38) was a convenience sample recruited by
posters exhibited at social welfare and GP offices. Controls and SUD
patients were compensated with NOK 400 (~USD 50) for the baseline
testing. During the one-year follow-up period, 13 SUD patients and four
people from the control group withdrew or dropped out of the study.
The final group included 115 SUD patients and 34 controls. The re-
tention rate was 89.8% for patients and 89.5% for controls. This study
was reviewed and approved by the Regional Ethical Committee (REK
2011/1877) and conducted according to its guidelines and those of the
Helsinki Declaration (1975). Written informed consent was obtained
from all participants.
2.2. Procedures
The study is part of a prospective cohort study of a sample of SUD
patients in the Stavanger University Hospital catchment area. To
minimize contamination from drug withdrawal and the acute neuro-
toxic effects of psychoactive substances, baseline assessment was per-
formed after two weeks of abstinence (Miller, 1985) by experienced and
trained staff. Information on substance use was assessed using the Al-
cohol Use Disorders Identification Test (AUDIT) (Bohn,
Babor, & Kranzler, 1995) and the Drug Use Disorders Identification Test
(DUDIT) (Voluse et al., 2012). At the one-year follow-up, patients were
defined as relapsing to a significant level of use if they had an AUDIT
score ≥ 8, or a DUDIT score ≥ 2 for women and≥ 6 for men (Bohn
et al., 1995; Voluse et al., 2012).
2.3. Adult ADHD self-report scale (ASRS)
The ASRS is a frequently used screening instrument for ADHD
(Kessler et al., 2005). It is composed of 18 items that reflect the
symptoms used to define ADHD according to the fifth edition of the
Diagnostic and statistical manual of mental disorders (DSMeV)
(Association, 2013). The results from this scale assess the presence of
ADHD symptoms, but on its own, it is not an adequate diagnostic tool.
Symptoms are rated on a 5-point Likert-type scale (0–4 = never,
rarely, sometimes, often, and very often), with a range of 0 to 72 for the
18-item instrument. This instrument has previously been validated in
SUD populations (Dakwar et al., 2012; Van de Glind et al., 2013).
In the present study, we included a sum score across all the 18 ASRS
items, a sum score for the ASRS items that assess inattention (items 1–4
and 7–11), and a sum score for the items that assess hyperactivity/
impulsivity (items 5, 6, and 12–18).
In order to highlight the severity of individual items in the ASRS, we
dichotomized responses to the ASRS items into “severe/not severe”
according to recommendations by Kessler et al. (Kessler et al., 2005).
Lastly, we used the “severe/not severe” dichotomized items to identify
clinically significant ASRS profiles. The ASRS profile was dichotomized
as “clinically significant” if ≥ 9 items were dichotomized as “severe”,
and "not clinically significant if< 9 items were dichotomized as se-
vere". This method is commonly used in clinical practice, and in line
with the original recommendations by Kessler et al. (Kessler et al.,
2005).
2.4. Statistical analyses
All analyses were performed using IBM SPSS v24 for Mac. Two-
tailed p-values< 0.05 were considered statistically significant. Data
were assessed for normality with histograms, Q–Q plots,
Kolmogorov–Smirnov tests, and Shapiro-Wilk tests. Visual inspection of
histograms and Q-Q-plots revealed that ASRS-scores at baseline and
1 year follow up did not deviate from normality. This was also evident
from the Kolmogorov-Smirnov test (D(149) = 0.05, p = 0.200; and
1 year D(149) = 0.06, p = 0.200, respectively) and Shapiro-Wilk test
(baseline w(149) = 0.99, p = 0.651; and 1 year w(149) = 0.99,
p = 0.327). Sub-analysis of normality for each participant group
yielded similar results (data not shown). As the data was normally
distributed, parametric statistics were used throughout. The statistical
procedures of the demographic variables have been published in a
previous paper (Hagen et al., 2017).
Mixed ANOVA was used to compare changes in abstainers,
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relapsers, and controls from baseline to the one-year follow-up.
Variables for which one group's responses differed from those of the
other two groups were expected to show a significant interaction. To
determine the cause of interaction effects, a paired samples t-test was
used to evaluate mean change from baseline to one-year within each
group. Effect sizes were calculated as Cohen's d for paired samples and
parametric data, where 0.5 was considered a medium effect and 0.8 was
considered a large effect (Cohen, 1988). Main effects were not inter-
preted in the presence of a statistically significant interaction
(Bordens & Abbott, 2002).
Lastly, the frequency of individual items dichotomized as severe was
estimated for each group (i.e., abstinent, relapsed, and control), and
changes in frequency during the one-year follow-up were investigated
for each item using a repeated measures ANOVA. As multiple com-
parisons were made, Bonferroni adjusted P-values (0.05/18 = 0.003)
were used to establish statistical significance.
3. Results
3.1. Group characteristics
We presented data for the clinical and demographic variables for
patients who remained abstinent for a year (N = 51), patients who
relapsed (N = 64), and controls (N = 34) in a previous paper (Hagen
et al., 2017). In short, patients and controls did not differ in age, but
controls were more often female (44% vs. 33%) and had a higher mean
level of education (14.2 vs. 11.8 years) and a higher mean IQ score
(105.5 vs. 98.2) at baseline. Three patients and five controls were<
18 years of age at the time of inclusion. Although there were no dif-
ferences in baseline demographic variables between the two SUD
groups, the abstinent group obtained a higher mean WASI IQ score
(100.7 vs. 95.8). As measured by the mean AUDIT/DUDIT score,
baseline levels of substance abuse did not differ between the two SUD
groups.
3.2. ASRS total score
At baseline, there was a significant difference (t = 6.4, p < 0.001)
in ASRS total score between patients (m = 34.7, SD = 10.7) and con-
trols (m = 21.2, SD = 11.4). At baseline, patients who relapsed during
the follow-up period had a higher ASRS total score than patients who
remained abstinent, but this difference was not statistically significant
(Table 1). Repeated measures ANOVA showed a significant effect of
group [F(2146) = 18.0, P < 0.001] and time [F(1146) = 25.7,
p < 0.001], and a significant group × time interaction [F(2146)
= 10.2, p < 0.001] (illustrated in Fig. 1). Follow-up analyses showed
that the interaction could be attributed to the significant alleviation of
ADHD symptoms in the abstinent group (t = 5.5, p < 0.001), with a
large effect size (d = 0.82), and significant symptom improvement in
the relapse group (t = 2.4, p = 0.017), with a moderate effect size
(d = 0.37). In the control group, the ASRS total score did not change
from baseline to one year later (m = 21.2, SD = 11.4 vs. m = 21.0,
SD = 9.4). At both time-points, the total score in the control group was
slightly lower than that at follow-up in the SUD patients who were
abstinent (m = 23.3, SD = 14.4), and considerably lower compared
with those who relapsed (m = 31.6, SD = 9.6).
3.3. Inattention symptoms
At baseline, there was a significant difference (t = 6.4, p < 0.001)
in inattention symptoms between patients (m = 18.6, SD = 6.4) and
controls (m = 10.6, SD = 6.1). The patient groups (abstained and re-
lapsed) did not differ at baseline on the ASRS inattention subscale.
Repeated measures ANOVA showed significant main effects of group [F
(2146) = 18.0, p < 0.001] and time [F(1146) = 21.1, P < 0.001],
and a significant group × time interaction [F(2146) = 10.2,
p < 0.001]. Follow-up analyses showed that the interaction could be
attributed to the significant improvement in the abstinent group
(t = 5.5, p < 0.001), with a medium to large effect size (d = 0.82),
and a significant improvement in the relapse group (t = 2.3,
p = 0.025), with a small effect size (d = 0.31). The ASRS inattention
score in the control group did not change over time.
3.4. Hyperactivity-impulsivity symptoms
At baseline, there was a significant mean difference (t = 6.4,
p < 0.001) between patients (m = 16.1, SD = 5.9) and controls
(m = 10.6, SD = 6.2) on the ASRS hyperactivity/impulsivity subscale.
The patient groups did not differ on this score at baseline, but the re-
peated measures ANOVA showed significant main effects for group [F
(2145) = 10.8, p < 0.001] and time [F(1145) = 17.9, p < 0.001],
and a significant group × time interaction [F(2145) = 5.4, p = 0.006].
Follow-up analyses showed that the interaction could be attributed to
significant improvement in the abstinent group (t = 4.5, p < 0.001),
with a moderate effect size (d = 0.66), and significant improvement in
Table 1

























































All data are means (SD).
a Results of paired samples t-test. This measures improvement in mean score from
baseline to one-year later within the group.
b Number with clinical score is indicated by [N].
⁎ p < 0.05.
⁎⁎⁎ p < 0.001.
Fig. 1. Mean ASRS sum score for each group at baseline and one-year follow up.
Footnote: Changes in mean ASRS sum score from baseline to one-year for each group.
Standard deviation indicated by error bars.
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the relapse group (t = 2.4, p = 0.021), with a small effect size
(d = 0.31). The change in the hyperactivity-impulsivity subscale was
not statistically significant for the control group.
3.5. ASRS scores indicating severe ADHD symptoms
The frequencies of number of severe ADHD symptoms (in total) for
each group are presented in Fig. 2. Overall, patients reported a sig-
nificantly higher number of severe symptoms than controls at baseline
(t = 6.1, p < 0.001). The frequency of severe symptoms did not differ
between the two patient groups at baseline (t = 0.6, p = 0.570). The
abstinent group demonstrated a significant decrease (t = 4.4,
p < 0.001) in severe symptoms from baseline (m = 7.3, SD = 4.3) to
1 year (m = 4.3, SD = 4.5), whereas the changes in the relapse group
(t = 2.0, p = 0.054) and the control group (t = −0.1, p = 0.937)
were not statistically significant.
The percentages of severe symptoms are presented for each group
on each ASRS item in Table 2. The control group had no statistically
significant change from baseline on any items of the ASRS. The relapse
group had significant change on two symptoms, but these did not
withstand Bonferroni correction for multiple comparisons. For the ab-
stinent group, eight items demonstrated a significant improvement
from baseline to the one-year follow-up, but only three items were
considered statistically significant following Bonferroni correction:
Item 8: sustained attention (F[1, 50] = 14.8, p < 0.001), Item 9:
concentration when listening (F[1, 50] = 24.3, p < 0.001), and Item
13: Restlessness (F[1, 50] < 27.3, p < 0.001).
4. Discussion
This study compared patients with polysubstance use disorder who
remained abstinent, patients who relapsed, and healthy controls on
changes in self-reported ADHD symptoms from baseline to follow-up
assessment one year later. The abstinent group showed a substantial
reduction of ADHD symptoms compared with the relapse and control
groups. In fact, the scores of the abstinent group at follow-up were only
slightly higher than those of the healthy controls, who were in the
normal range for ADHD symptoms at both baseline and follow-up. The
improvements in the abstinence group were particularly prominent on
the ASRS items that reflect problems related to sustained attention,
concentration, and restlessness.
4.1. Improvement of self-reported ADHD symptoms
SUD complicates diagnostic procedures and accuracy for patients
with comorbid ADHD symptoms of hyperactivity, impulsivity, and in-
attention. These symptoms are, however, not restricted to individuals
with an ADHD diagnosis. Patients with SUD can develop impulsivity
and hyperactivity, and have difficulty with attention as a result of the
neurotoxic effects of the drugs that they use and the lifestyle associated
with SUD (Yuan et al., 2009). Impulsivity and executive dysfunctions
have been associated with almost all stages of SUD (Stevens et al.,
2014), as individuals with these characteristics have an increased
probability of starting to use drugs, more destructive intensification of
use, and more relapses after treatment (Jentsch, 2009; Robbins, Gillan,
Smith, de Wit, & Ersche, 2012; Winstanley, Olausson, Taylor, & Jentsch,
2010).
Systematic use of screening tools to identify ADHD in childhood is
rare, which creates a risk of leaving cases undetected (Wilens et al.,
2011). If these individuals later develop SUD, their attentional and
impulsivity problems may be addressed for the first time as part of the
initial diagnostic work in the SUD. Our findings suggest that active SUD
and the associated lifestyle could account for some of the problems
related to sustained attention, concentration, and restlessness, as these
ADHD symptoms were substantially reduced in our clinical sample after
one year of abstinence. The clinical importance of this result is
strengthened by previous studies with the same cohort that have de-
monstrated improved executive functions, increased satisfaction with
life, and reduced psychological distress (Hagen et al., 2017). Thus, our
findings support the recommendation from previous research that there
should be a “treatment hierarchy” that begins with treatment of the
most prominent SUD symptoms and stabilization of the drug addiction
(Wilens, 2004).
The reduction in ADHD symptoms in the two polysubstance use
disorder groups in this study was compelling. The abstinence group
showed a more profound reduction in severe ADHD symptoms, but the
relapse group also showed some improvements. It is possible that, on
average, SUD treatment improves ADHD symptomatology because it
introduces a period of stability and reduces substance use. Several
psychosocial treatments are recommended for SUD and comorbid
mental disorders, including motivational interviewing, cognitive-be-
havioral therapy, contingency management, relapse prevention, case
management, and social skills training (Horsfall, Cleary,
Hunt, &Walter, 2009). To make behavioral changes, these treatments
for SUD require cognitive processing and learning abilities
(Roehrich & Goldman, 1993). This could involve learning about pro-
gram rules, treatment philosophy, and the negative effects of different
drugs (Grohman & Fals-Stewart, 2003), all of which represent a sub-
stantial learning requirement at the onset of therapy. However, the
present results suggest that a slow, careful, stepwise approach to
learning requirements should be adopted in treatment, one that initially
focuses on stabilizing the patient, providing structure, and supporting
abstinence from substance use.
Diagnosing ADHD with active SUD is challenging. The risk of false-
positive ADHD diagnoses in patients assessed by ASRS has been re-
ported (Lugoboni et al., 2017; Roncero et al., 2015). Thus, our finding is
a reminder that a period of abstinence, preferably evident by urine tests
or other means of substance monitoring, should be in place before
providing conclusions regarding an ADHD diagnosis.
4.2. Strengths and limitations
Many studies in this field have used cross-sectional designs (van
Holst & Schilt, 2011), and thus they were unable to track longitudinal
changes. We used a prospective design for the patient and control
groups, which allowed us to monitor possible training effects through
repeated testing and reports on the same questionnaires (Schulte et al.,
2014). However, there was a significant difference in years of
Fig. 2. Mean frequency of severe ADHD symptoms (in total) for each group.
Footnote: Changes in frequency of severe ADHD symptoms from baseline to one-year for
each group.
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education, gender, and work experience between the patients and
controls. Regarding education, all Norwegian citizens receive compul-
sory education from 5 to 16 years of age. Hence, it was difficult to re-
cruit age-matched participants with fewer than 10 years of education
who did not use drugs.
The present study has several other limitations. First, the patients in
the relapse and abstinence groups were self-selected (based on their
self-reports), and time-sensitive variables that we did not assess may
have influenced our outcome variables. Thus, we cannot conclude that
the differences in the outcomes observed at 12 months were only
caused by changes in substance use status. Furthermore, we only as-
sessed ADHD symptoms at baseline and one-year follow-up; therefore,
we cannot determine when the abstinence group's improvements in
ADHD symptoms occurred during the follow-up period. In addition, the
assessment of ADHD symptoms with ASRS does not constitute a full
diagnostic procedure. Without historical anamnestic data in our study,
it is difficult to suggest whether the alleviation of symptoms only ap-
plies to a subthreshold group of patients or if it is also associated with
late-onset ADHD diagnosis.
Future research should include longitudinal prospective cohort
studies with repeated measures of the trajectories of ADHD sympto-
matology in SUD patients. The presence or absence of ADHD should be
assessed at baseline or collected from hospital journal data whenever
possible. Cohort studies assessing ADHD in childhood, focusing on the
participants developing SUD later in the trajectory, could provide va-
luable information and possibly explain the mechanism behind the
findings presented here.
5. Conclusions
To our knowledge, this is the first study to report improvement of
ADHD symptoms for people with polysubstance use disorder during a
12-month treatment sequence. Our data suggest that there is a clinically
(as well as a statistically) significant reduction in self-reported ADHD
symptoms for SUD patients following one year of abstinence. This is
useful knowledge for patients suffering from comorbid SUD and ADHD,
as well as for clinicians. Our finding is a reminder that the assessment of
ADHD should follow a period of abstinence to avoid false-positive
ADHD diagnoses. Instead of focusing on ADHD as a persistent disorder,
treatment should focus on how supporting stable abstinence may re-
duce ADHD-like symptoms.
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18 Interrupts 11.8 5.9 10.9 6.25 2.9 2.9
% = percentage of participants with self-reported severe symptoms within this group. ASRS, Adult ADHD Self-Report Scale.
a Comparison between baseline and one-year follow-up.
b Significant after Bonferroni correction.
⁎ p < 0.05.
⁎⁎ p < 0.01.
⁎⁎⁎ p < 0.001.
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